Description

Cooper Companies’ $650 Million Cash Flow Raise: Fuel For A Portfolio Reshape?

The Cooper Companies reported its second-quarter fiscal 2026 results with consolidated revenue increasing 8% year-over-year to $1.08 billion and non-GAAP earnings per share rising 26% to $1.21. This marked the company’s tenth consecutive quarter of surpassing consensus earnings expectations and was driven by growth across both operating segments: CooperVision and CooperSurgical. CooperVision’s revenue grew 8% (4% organically), led by strong performance in the Americas and EMEA, offset partially by a 6% decline in Asia Pacific due to portfolio rationalization and broader regional softness, particularly in Japan. Premium daily silicone hydrogel lenses, including MyDay, and myopia control product MiSight (which grew 24%) contributed meaningfully to CooperVision’s results. CooperSurgical’s revenues increased 8% (6% organically), with the fertility division particularly strong, growing 10% organically driven by capital equipment, genomics, and consumables, leading to market share gains especially in EMEA and the Americas.